Last updated on September 2018

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Heart Failure
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Willing and able to provide written informed consent and accept study procedures and time schedule.
  • Age 18 years.
  • Patients suffering from chronic heart failure (the heart failure diagnosis must have been made or confirmed by a cardiologist and/or hospital physician at any time in the patient's medical history).
  • Patients with reduced ejection fraction ( 40%) as confirmed at any time point in the patient's medical history.

Exclusion Criteria:

  • Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
  • Major surgery in the last 3 months prior to baseline or planned major surgery or cardiac intervention during the study.
  • Cancer or other significant co-morbidities implying that the patient's condition is unstable.
  • Comorbidities that can be associated with elevated natriuretic peptide (NP) levels: renal insufficiency, (eGFR < 25 ml/min/1.73 m calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months.
  • Patients who are primarily managed and regularly followed-up by a cardiologist for their HF
  • Highly frail patients whose estimated lifespan due to comorbidities by the judgement of the investigator is less than 6 months.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.